CD40 and cancer: The researchers forwarded the hypothesis that the pro-thrombotic agents released from lung cancer cells stimulate platelet activation and release of sCD40L, which in turn interacts with other types of CD40-positive cells, including tumor-associated macrophage (TAM) cells and cancer cells of the lungs.